Virtus Biotech Clinical Trials ETF (BBC) is a healthcare and biotech ETF. As of October 9, 2026, ETF Copilot scores BBC 1.5 out of 10 — highest on Return (4.0), lowest on Risk (0.2). Its ten largest holdings are 14% of the fund.
What stands out in BBC's data
A focused strategy tied to biotech clinical-trial activity.
Profitability trails most peers — these are pre-revenue companies, not yet earning.
EBITDA margin of 3.2% sits behind most peers and below its own 2.4% historical median. The 0.65% expense ratio is above average for the category.
A niche sleeve for portfolios already holding broad health-care exposure.
Why did BBC move this week? It fell 0.9% in the week to October 9, 2026 — Arrivent Biopharma and Abcellera Biologics drove it
BBC fell 0.9% in the week to October 9, 2026. The holdings that moved it most were Arrivent Biopharma (−40.8%), Abcellera Biologics (−8.7%) and MBX Biosciences (−9.0%); Prime Medicine (+33.9%) pushed the other way.
How is BBC rated? ETF Copilot scores Virtus Biotech Clinical Trials ETF (BBC) 1.5 out of 10
As of October 9, 2026, ETF Copilot scores Virtus Biotech Clinical Trials ETF (BBC) 1.5 out of 10 overall.
ETF Copilot scores (0–10 scale, higher is better):
- Overall: 1.5 / 10
- Risk: 0.2 / 10
- Quality: 0.2 / 10
- Return: 4.0 / 10
What's inside BBC?
What's inside BBC: Size (Large 1%, Mid 12%, Small 87%); Geography (International 11%, US 89%).
What are BBC's top holdings? The ten largest are 14% of the fund
Kodiak Sciences, Abcellera Biologics, Xencor, Amylyx Pharmaceuticals, First Tracks Biotherapeutics, MBX Biosciences, Replimune, Oric Pharmaceuticals, Sellas Life Sciences and 4D Molecular Therapeutics are BBC's largest holdings, in that order.
Less concentrated than 99% of Health & Biotech ETFs.
Half of BBC's weight sits in its 49 largest positions, and once those weights are taken into account it behaves like 114 equally weighted holdings.
What is BBC's expense ratio? 0.65% a year
As of October 9, 2026, BBC charges 0.65% a year, yields 1.50% and holds $41M in assets across 129 positions.
| Measure | BBC |
|---|---|
| Expense ratio | 0.65% |
| Dividend yield | 1.50% |
| Assets under management | $41M |
| Holdings | 129 |
Expense ratio, dividend yield and assets under management are reported by the fund and refreshed daily. Every other figure on this page is computed by ETF Copilot.
Cite this
ETF Copilot, “Virtus Biotech Clinical Trials ETF (BBC) scores and holdings analysis”, as of October 9, 2026.
https://etf-copilot.com/etf/bbc
ETF Copilot Pro unlocks BBC's price and what each holding weighs.
Try Pro free →